User contributions for Edzelco

19:0519:05, 10 February 2024 diff hist +19 User:Edzelco →Pages Authored/Co-authored/Collaborated
19:0519:05, 10 February 2024 diff hist +23 Oteseconazole No edit summary current
19:0419:04, 10 February 2024 diff hist +25,740 N Oteseconazole Created page with "{{DrugProjectFormSinglePage |genericName=oteseconazole |aOrAn=an |drugClass=azole antifungal |indicationType=prevention |indication=recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential |adverseReactions=headache and nausea |fdaLIADAdult=VIVJOA Capsules: 150 mg of oteseconazole in lavender hard gelatin capsules imprinted with OTE 150 in black ink. Fluconazole is not supplied in the carton. |co..."
19:0219:02, 10 February 2024 diff hist 0 N File:VIVJOA label3.png No edit summary current
19:0219:02, 10 February 2024 diff hist 0 N File:VIVJOA label2.png No edit summary current
19:0219:02, 10 February 2024 diff hist 0 N File:VIVJOA label.png No edit summary current
19:0219:02, 10 February 2024 diff hist 0 N File:VIVJOA structure.png No edit summary current
18:4718:47, 10 February 2024 diff hist −18 User:Edzelco →Edzel Lorraine Co, DMD, MD

00:5700:57, 6 February 2024 diff hist +35 User:Edzelco →Pages Authored/Co-authored/Collaborated
00:5700:57, 6 February 2024 diff hist +33,106 N Nivolumab and relatlimab-rmbw Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=nivolumab and relatlimab-rmbw |aOrAn=a |drugClass=combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody |indicationType=treatment |indication=adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma |adverseReactions=immune-mediated pneumonitis, im..." current
00:5600:56, 6 February 2024 diff hist 0 N File:Nivolumab and relatlimab-rmbw label.png No edit summary current
00:2600:26, 6 February 2024 diff hist +16 User:Edzelco →Pages Authored/Co-authored/Collaborated
00:2300:23, 6 February 2024 diff hist −2 Ganaxolone No edit summary current
00:2300:23, 6 February 2024 diff hist +24,999 Ganaxolone No edit summary
00:2200:22, 6 February 2024 diff hist 0 N File:Ganaloxone bottle carton.png No edit summary current
00:2200:22, 6 February 2024 diff hist 0 N File:Ganaloxone bottle suspension label 50mg.png No edit summary current
00:2100:21, 6 February 2024 diff hist 0 N File:Ganaloxone structure.png No edit summary current

15:4915:49, 2 February 2024 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
15:4915:49, 2 February 2024 diff hist +16 User:Edzelco →Pages Authored/Co-authored/Collaborated
15:4815:48, 2 February 2024 diff hist −2 Pacritinib No edit summary current
15:4715:47, 2 February 2024 diff hist +29,299 N Pacritinib Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Pacritinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L (1) |adverseReactions=diarrhea, thrombocytopenia, nausea, anemia, and peripheral edema |fdaLIADAdult=The recommended dosage of VONJO is 200 mg orally twi..."
15:4715:47, 2 February 2024 diff hist 0 N File:Pacritinib Bottle Label.png No edit summary current
15:4715:47, 2 February 2024 diff hist 0 N File:Pacritinib Carton Label.png No edit summary current
15:4715:47, 2 February 2024 diff hist 0 N File:Pacritinib supply.png No edit summary current
15:4715:47, 2 February 2024 diff hist 0 N File:Pacritinib structure.png No edit summary current

Navigation menu